Natiijooyinka caafimaad ee hordhaca ah ee Fapilavir ee daaweynta COVID-19 ayaa la heli karaa! Wuxuu ciribtiraa fayraska 4 maalmood gudahood isagoo leh badbaado wanaagsan iyo dulqaad.

Fapilavir

Natiijooyinka caafimaad ee hordhaca ah ee Fapilavir ee daaweynta COVID-19 ayaa la heli karaa! Wuxuu ciribtiraa fayraska 4 maalmood gudahood isagoo leh badbaado wanaagsan iyo dulqaad.
 
"Daraasad Caafimaad oo ku saabsan Amniga iyo Waxtarka Fapilavir ee Daaweynta Bukaannada qaba cudurka 'Coronavirus Pneumonia' cusub (COVID-19) (Lambarka Diiwaangelinta: ChiCTR2000029600) oo lagu xusay shirkii jaraa'id ee kooxda cilmi baarista sayniska ee wadajirka kahortagga iyo xakamaynta ee Wasaaradda Sayniska iyo Teknolojiyada ayaa soo baxday.

Cilmi baaris ayaa soo jeedisay in favipiravir ay yareyn karto horumarka COVID-19 iyadoo la dardar galinayo nadiifinta viruska. Cilmi-baarista waxaa soo gabagabeeyay kooxda Liulei iyo Liu Yingxia oo ka socda Xarunta Cilmi-baarista injineernimada Qaranka ee Ka-hortagga iyo Xakamaynta Degdegga ah iyo Isbitaalka Dadka Saddexaad ee Magaalada Shenzhen.

Nadiifinta fayrasku waa heerka ugu weyn ee caalamku aqbalay ee lagu qiimeeyo waxtarka caafimaad ee daawooyinka fayraska looga hortago. In "Daraasad Caafimaad oo ku saabsan Amniga iyo 

Maaddooyinka Favipiravir

Waxtarka Fapilavir ee Daaweynta Novel Coronavirus Pneumonia (COVID-19) Bukaannada (Diiwaangelinta Maya. ChiCTR2000029600) ", 35 bukaan ah oo qaba COVID-19 caadi ah oo buuxiyay shuruudaha u qalmitaanka ayaa la aqbalay daaweynta Favipiravir (3200 mg maalinta ugu horreysa, 1200 mg / d maalmaha 2aad ilaa 14aad, oo loo qaybiyay laba qiyaasood oo afka ah, habka daaweynta ayaa soconaya ilaa laga nadiifiyo fayraska ama maalinta 14aad).

Daraasadda waxaa sidoo kale ku jiray 45 bukaan ah oo qaba COVID-19 kuwaas oo lagu daaweeyay kiniiniyada lopinavir / ritonavir (400mg / 100mg, laba jeer maalintii, hadal ahaan) da'da u dhiganta, jinsiga, iyo darnaanta cudurka sida kooxda xakamaynta. Isbarbardhiga waqtiga dhexdhexaadka ah ee qaadashada daroogada illaa nadiifinta fayraska, heerka hagaajinta shucaaca xabadka iyo amniga maalinta 14th ee daaweynta ayaa la barbardhigay labada koox.

Natiijooyinka waxay muujiyeen in dhammaan astaamaha aasaasiga ah ee labada koox ee bukaanku ay ahaayeen kuwo la barbardhigi karo. Waqtiga dhexdhexaadka ee nadiifinta fayrasku wuu ka yaraa kooxda daaweynta Favipiravir, oo leh dhexdhexaad (dhexdhexaad dhexdhexaad ah) oo ah 4 maalmood (2.5-9 maalmood) iyo koox kantarool ah oo ah 11 maalmood (8-13 maalmood), iyadoo faraq weyn u dhexeeya labada kooxaha (P <0.001).

Ka dib markii la xakameeyay waxyaalaha khalkhalka keeni kara (da'da, waqtiga bilawga, qandhada, iwm.), Favipiravir wali waa cunsur saameyn madaxbanaan ku leh hagaajinta sawirka xabadka iyo nadiifinta fayraska hore. Marka la barbardhigo kooxda xakamaynta, kooxda favipiravir waxay lahaayeen falcelinno yar oo dulqaad leh. Natiijooyinka cilmi-baarista waxaa loo gudbiyay joornaalka Akadeemiyada Shiinaha ee Injineerinka.

Waa maxay Fapilavir?

Fapilavir waa mid ka mid ah seddex daroogo oo ay diiradda saaraan kooxda cilmi baarista sayniska.

Waxaa sidoo kale loo yaqaan Favilavir ama Avigan, oo ay soo saareen Toyama kiimikada co., Ltd. ee Japan.

Tani waa daawo tijaabo ah oo kahortaga hargabka, oo ka tirsan daroogada ballaaran ee anti-RNA virus, oo leh firfircooni ka dhan ah fayrasyo ​​badan oo RNA ah. Sannadkii 2014, waxaa laga ansixiyay Japan inuu noqdo keyd loogu talagalay ka hortagga ifilada safka ah.

Tijaabooyinkii hore waxay muujiyeen in fapilavir uu saameyn gaar ah ku leeyahay fayraska Ebola. 

Natiijooyinka ka soo baxay tijaabooyinkii sanadkii 2015-kii waxay muujiyeen inay yareyn karto dhimashada bukaannada qaba heerarka dhiigga ee hooseeya ama dhexdhexaadka ah ee fayraska Ebola.

Fapilavir sidoo kale wuxuu si wax ku ool ah u xakameeyaa fayraska Ebola, viruska qandhada huruuda, Chikungunya virus, iyo norovirus. Daraasaddii ugu dambaysay waxay muujisay in tijaabooyinka qadka fitamiinada ku jira, EC50-keeda oo ka dhan ah viruska neocrown ay gaareen 61.88 μM.

Tijaabooyinkii caafimaad ee ku xigay ee COVID-19, fapilavir waxay si tartiib tartiib ah u muujisay waxtarkeeda.

Isbitaalka Shenzhen Trinity Hospital ee kaqeybgalaya ayaa shaaca ka qaaday gabagabada in Fapilavir ay tahay mid amaan ah oo wax ku ool ah, taas oo saameynteeda kahortaga fayrasku ay kafiican tahay tan kintirka, waxyeelada ay leedahay sidoo kale aad ayey ugayartahay tan kintirka. Waxaa lagugula talinayaa inaad ballaariso cabirka dalabka daaweynta.

Bishii Febraayo 15, shirkii jaraa'id ee kahortagga iyo xakameynta habka wadajirka ah ee Golaha Gobolka, Zhang Xinmin, oo ah agaasimaha Xarunta Cilmiga Biyoolajiga ee Wasaaradda Sayniska iyo Teknolojiyada, ayaa sii muujiyay natiijooyinka caafimaad:

Fapilavir waa daroogada dibada loogu suuq geeyo daaweynta hargabka. kuwaas oo ku socday tijaabooyin caafimaad oo adag oo ku yaal Shenzhen. In ka badan bukaanno 70 ayaa la qoray, oo ay ku jiraan kooxda kantaroolka, oo markii hore muujisay waxtar muuqda iyo falcelin xun. Laga soo bilaabo 3 illaa 4 maalmood daaweynta ka dib, heerka fayraska 'nucleic acid acid beddelaadda' ee kooxda daweynta ayaa si weyn uga sarreeyay kan kooxda xakamaynta.

Isla maalintaas, Fapilavir waxaa si rasmi ah loogu ansixiyay suuq gaynta Maamulka Dawada Dawladeed, isagoo noqday dawadii ugu horaysay ee dalka ku yeelata saameyn daaweyn ee COVID-19 intii lagu jiray faafida.

fure :Favipirav waa, Soo iibso Favipiravir, iibinta Favipiravir, Soosaaraha Favipiravir, Favipiravir Daad, Alaabada ceeriin ee badan, Bulk Favipiravir, Favipiravir waxyaabaha, Favipiravir Factory